$BCYC
Bicycle Therapeutics PLC

2022 Q4 Form 10-Q Financial Statement

#000155837022016140 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $3.185M $3.040M
YoY Change -15.54% -29.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.72M $10.25M
YoY Change 18.01% 23.94%
% of Gross Profit
Research & Development $24.72M $22.75M
YoY Change 90.79% 116.42%
% of Gross Profit
Depreciation & Amortization $1.386M $1.300M
YoY Change 240.54% 333.33%
% of Gross Profit
Operating Expenses $35.43M $32.80M
YoY Change 60.8% 76.08%
Operating Profit -$29.76M
YoY Change 108.19%
Interest Expense $1.851M $817.0K
YoY Change -455.96% -0.73%
% of Operating Profit
Other Income/Expense, Net $1.174M
YoY Change -246.93%
Pretax Income -$30.40M -$28.59M
YoY Change 61.82% 89.39%
Income Tax -$420.0K -$200.0K
% Of Pretax Income
Net Earnings -$29.98M -$28.30M
YoY Change 66.2% 92.52%
Net Earnings / Revenue -941.22% -930.92%
Basic Earnings Per Share -$0.96
Diluted Earnings Per Share -$1.01 -$0.96
COMMON SHARES
Basic Shares Outstanding 29.69M 29.68M
Diluted Shares Outstanding 29.68M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.2M $361.5M
YoY Change -22.69% 39.28%
Cash & Equivalents $339.2M $361.5M
Short-Term Investments
Other Short-Term Assets $9.022M $8.448M
YoY Change 13.27% 49.68%
Inventory
Prepaid Expenses
Receivables $2.045M $0.00
Other Receivables $19.16M $11.37M
Total Short-Term Assets $369.4M $381.3M
YoY Change -19.45% 39.73%
LONG-TERM ASSETS
Property, Plant & Equipment $19.11M $16.22M
YoY Change 511.91% 565.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.458M $6.159M
YoY Change 145.3% 121.71%
Total Long-Term Assets $41.23M $35.86M
YoY Change 94.12% 323.86%
TOTAL ASSETS
Total Short-Term Assets $369.4M $381.3M
Total Long-Term Assets $41.23M $35.86M
Total Assets $410.6M $417.1M
YoY Change -14.42% 48.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.472M $7.057M
YoY Change 137.85% 300.74%
Accrued Expenses $26.45M $18.09M
YoY Change 85.71% 65.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.34M $41.55M
YoY Change 47.2% 37.69%
LONG-TERM LIABILITIES
Long-Term Debt $30.32M $30.23M
YoY Change 1.48% 1.61%
Other Long-Term Liabilities $3.829M $3.157M
YoY Change 16.77% 3.81%
Total Long-Term Liabilities $34.14M $33.39M
YoY Change 2.99% 1.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.34M $41.55M
Total Long-Term Liabilities $34.14M $33.39M
Total Liabilities $139.8M $127.7M
YoY Change 4.71% 15.53%
SHAREHOLDERS EQUITY
Retained Earnings -$331.1M -$301.1M
YoY Change 51.62% 50.32%
Common Stock $387.0K $385.0K
YoY Change 0.78% 17.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $270.8M $289.5M
YoY Change
Total Liabilities & Shareholders Equity $410.6M $417.1M
YoY Change -14.42% 48.28%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$29.98M -$28.30M
YoY Change 66.2% 92.52%
Depreciation, Depletion And Amortization $1.386M $1.300M
YoY Change 240.54% 333.33%
Cash From Operating Activities -$30.31M -$5.871M
YoY Change 190.46% -127.03%
INVESTING ACTIVITIES
Capital Expenditures $1.448M -$2.984M
YoY Change -235.71% 1665.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.448M -$2.984M
YoY Change 35.71% 1665.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.888M 159.0K
YoY Change -96.91% -99.61%
NET CHANGE
Cash From Operating Activities -30.31M -5.871M
Cash From Investing Activities -1.448M -2.984M
Cash From Financing Activities 5.888M 159.0K
Net Change In Cash -25.87M -8.696M
YoY Change -114.44% -114.03%
FREE CASH FLOW
Cash From Operating Activities -$30.31M -$5.871M
Capital Expenditures $1.448M -$2.984M
Free Cash Flow -$31.76M -$2.887M
YoY Change 238.99% -113.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
24000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36238000
dei Entity Address City Or Town
EntityAddressCityOrTown
Great Abington, Cambridge,
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB21 6GS
dei City Area Code
CityAreaCode
+44
dei Local Phone Number
LocalPhoneNumber
1223 261503
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29689471
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
361469000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
438680000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8448000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7965000
CY2022Q3 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
11368000
CY2021Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
10910000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
381285000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
458555000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16220000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1991000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13484000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14666000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6159000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000
CY2022Q3 us-gaap Assets
Assets
417148000
CY2021Q4 us-gaap Assets
Assets
479792000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7057000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2721000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18091000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16404000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19273000
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38916
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
41552000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29676021
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25039990
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29643502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23719124
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001761612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29676021
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25039990
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29643502
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23719124
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29579364
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29678431
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Blocks A & B, Portway Building, Granta Park
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30232000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29873000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10997000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12081000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41736000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
52067000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3157000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3279000
CY2022Q3 us-gaap Liabilities
Liabilities
127674000
CY2021Q4 us-gaap Liabilities
Liabilities
133538000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29678431
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29579364
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
385000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
384000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
589679000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
567637000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
528000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3388000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301118000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218379000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
289474000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
417148000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
479792000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3040000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11278000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7926000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22752000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10513000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56890000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31924000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10047000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8114000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38830000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23596000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
32799000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
18627000
us-gaap Operating Expenses
OperatingExpenses
95720000
us-gaap Operating Expenses
OperatingExpenses
55520000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29759000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14294000
us-gaap Operating Income Loss
OperatingIncomeLoss
-84442000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47594000
us-gaap Interest And Other Income
InterestAndOtherIncome
3117000
us-gaap Interest And Other Income
InterestAndOtherIncome
61000
CY2022Q3 us-gaap Interest Expense
InterestExpense
817000
CY2021Q3 us-gaap Interest Expense
InterestExpense
823000
us-gaap Interest Expense
InterestExpense
2518000
us-gaap Interest Expense
InterestExpense
2164000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1174000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-799000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
599000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2103000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28585000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15093000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83843000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49697000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-238000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-415000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1104000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-915000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28347000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14678000
us-gaap Net Income Loss
NetIncomeLoss
-82739000
us-gaap Net Income Loss
NetIncomeLoss
-48782000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29676021
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25039990
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29643502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23719124
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28347000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14678000
us-gaap Net Income Loss
NetIncomeLoss
-82739000
us-gaap Net Income Loss
NetIncomeLoss
-48782000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
902000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
313000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3916000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27445000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14365000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78823000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48782000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10198000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5673000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2094000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
311392000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
159000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5368000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
902000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28347000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
289474000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95460000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1800000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58775000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3821000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-58000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16191000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
142091000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1575000
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13977000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2575000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-255000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17913000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
142050000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3049000
CY2021Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
900000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29843000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2688000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
313000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14678000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
170823000
us-gaap Profit Loss
ProfitLoss
-82739000
us-gaap Profit Loss
ProfitLoss
-48782000
us-gaap Share Based Compensation
ShareBasedCompensation
21239000
us-gaap Share Based Compensation
ShareBasedCompensation
9084000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2303000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1002000
bcyc Non Cash Interest Expense
NonCashInterestExpense
359000
bcyc Non Cash Interest Expense
NonCashInterestExpense
347000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-348000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5544000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
3064000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
-1318000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2137000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
719000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2015000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
2024000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2640000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
955000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4931000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
270000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5495000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-521000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1446000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2123000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-969000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
28473000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
503000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
481000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55802000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4359000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17539000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
963000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17539000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-963000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
102595000
bcyc Proceeds From Issuance Of Ordinary Shares Pursuant Share Purchase Agreement
ProceedsFromIssuanceOfOrdinarySharesPursuantSharePurchaseAgreement
7558000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
804000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4908000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
804000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
130061000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4674000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1205000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-77211000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
123534000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
438680000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135990000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
361469000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259524000
us-gaap Interest Paid Net
InterestPaidNet
2099000
us-gaap Interest Paid Net
InterestPaidNet
1753000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1203000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
87000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
2245000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
676000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
318000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
298000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3120000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
361500000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28300000
us-gaap Net Income Loss
NetIncomeLoss
-82700000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14700000
us-gaap Net Income Loss
NetIncomeLoss
-48800000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue recognition, share-based compensation expense, valuation of right-of-use assets and liabilities, and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q3 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
300000
bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
1100000
CY2021Q3 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
1000000.0
bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
2900000
CY2022Q3 bcyc Remaining Government Grant Funding For Future Cost Reimbursement
RemainingGovernmentGrantFundingForFutureCostReimbursement
1300000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
503000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
30232000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
29873000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
276100000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
100000000.0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22240000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7923000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6020000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4800000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16220000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q3 us-gaap Depreciation
Depreciation
1300000
us-gaap Depreciation
Depreciation
2200000
CY2021Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
1000000.0
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6328000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6429000
CY2022Q3 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
7223000
CY2021Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3980000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1052000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
882000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2811000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2383000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
677000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
570000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18091000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q3 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2022Q3 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2022Q3 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q3 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
624000
CY2021Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
376000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
392000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
31500000
CY2022Q3 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
bcyc Number Of Voter Per Share
NumberOfVoterPerShare
1
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5368000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2688000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21239000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9084000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35156000
CY2021 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
49056000
CY2021 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11697000
CY2021 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
1175000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3040000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4333000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11278000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7926000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
10000000
bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11278000
bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
11922000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
58140000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000
CY2022Q3 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3040000
CY2021Q3 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3206000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
10072000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
6263000
CY2021Q3 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1127000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1206000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1507000
bcyc Contract With Customer Liability Revenue Recognized On Changes In Transaction Price
ContractWithCustomerLiabilityRevenueRecognizedOnChangesInTransactionPrice
156000
CY2022Q3 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
3040000
CY2021Q3 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
4333000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
11278000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
7926000
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1100000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
924000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
273000
us-gaap Operating Lease Cost
OperatingLeaseCost
2866000
us-gaap Operating Lease Cost
OperatingLeaseCost
773000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
410000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
222000
us-gaap Variable Lease Cost
VariableLeaseCost
1005000
us-gaap Variable Lease Cost
VariableLeaseCost
444000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1334000
CY2021Q3 us-gaap Lease Cost
LeaseCost
495000
us-gaap Lease Cost
LeaseCost
3871000
us-gaap Lease Cost
LeaseCost
1217000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0703
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0789
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
868000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3718000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3740000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3763000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3045000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
821000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2147000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13808000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2811000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10997000
bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
bcyc Period Of Royalty Payments Agreed Under Arrangement
PeriodOfRoyaltyPaymentsAgreedUnderArrangement
P10Y
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28347000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14678000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82739000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48782000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29676021
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25039990
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29643502
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23719124
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5972306
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4717166
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q3 us-gaap Noncurrent Assets
NoncurrentAssets
29704000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
17789000

Files In Submission

Name View Source Status
0001558370-22-016140-index-headers.html Edgar Link pending
0001558370-22-016140-index.html Edgar Link pending
0001558370-22-016140.txt Edgar Link pending
0001558370-22-016140-xbrl.zip Edgar Link pending
bcyc-20220930.xsd Edgar Link pending
bcyc-20220930x10q.htm Edgar Link pending
bcyc-20220930xex10d1.htm Edgar Link pending
bcyc-20220930xex31d1.htm Edgar Link pending
bcyc-20220930xex31d2.htm Edgar Link pending
bcyc-20220930xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bcyc-20220930_def.xml Edgar Link unprocessable
bcyc-20220930_pre.xml Edgar Link unprocessable
bcyc-20220930_lab.xml Edgar Link unprocessable
bcyc-20220930x10q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcyc-20220930_cal.xml Edgar Link unprocessable